Brokerages Set Actinium Pharmaceuticals, Inc. (NYSE:ATNM) Target Price at $7.40

Actinium Pharmaceuticals, Inc. (NYSE:ATNM) has received a consensus rating of “Moderate Buy” from the five brokerages that are currently covering the stock, Marketbeat reports. One analyst has rated the stock with a hold rating and four have given a buy rating to the company. The average 1 year target price among analysts that have covered the stock in the last year is $7.40.

Several brokerages recently commented on ATNM. HC Wainwright reaffirmed a “buy” rating and issued a $4.00 price objective on shares of Actinium Pharmaceuticals in a research report on Tuesday, March 11th. Stephens reaffirmed an “overweight” rating and issued a $5.00 price objective on shares of Actinium Pharmaceuticals in a research report on Tuesday, November 19th.

Actinium Pharmaceuticals Stock Up 2.5 %

Shares of Actinium Pharmaceuticals stock opened at $1.23 on Tuesday. The firm has a market capitalization of $38.37 million, a P/E ratio of -0.88 and a beta of 0.10. The company has a 50 day moving average price of $1.21 and a 200 day moving average price of $1.47. Actinium Pharmaceuticals has a 52 week low of $1.03 and a 52 week high of $10.24.

Hedge Funds Weigh In On Actinium Pharmaceuticals

Several hedge funds and other institutional investors have recently bought and sold shares of the business. Vontobel Holding Ltd. acquired a new stake in shares of Actinium Pharmaceuticals during the 4th quarter worth approximately $32,000. Sei Investments Co. acquired a new stake in shares of Actinium Pharmaceuticals during the 4th quarter worth approximately $62,000. Barclays PLC grew its stake in shares of Actinium Pharmaceuticals by 323.0% during the 3rd quarter. Barclays PLC now owns 42,935 shares of the company’s stock worth $81,000 after purchasing an additional 32,784 shares during the period. Bank of America Corp DE grew its stake in shares of Actinium Pharmaceuticals by 76.6% during the 4th quarter. Bank of America Corp DE now owns 78,767 shares of the company’s stock worth $99,000 after purchasing an additional 34,176 shares during the period. Finally, Wellington Management Group LLP acquired a new stake in shares of Actinium Pharmaceuticals during the 3rd quarter worth approximately $112,000. Institutional investors and hedge funds own 27.50% of the company’s stock.

About Actinium Pharmaceuticals

Actinium Pharmaceuticals, Inc develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. Its Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML).